Cardio Diagnostics (NASDAQ:CDIO) versus Scinai Immunotherapeutics (NASDAQ:SCNI) Head to Head Analysis

Scinai Immunotherapeutics (NASDAQ:SCNI) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, dividends, institutional ownership, risk and earnings.

Profitability

This table compares Scinai Immunotherapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Insider and Institutional Ownership

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Scinai Immunotherapeutics has a beta of 2.13, meaning that its share price is 113% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.29, meaning that its share price is 129% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Scinai Immunotherapeutics and Cardio Diagnostics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1	0	0	0	1.00
Cardio Diagnostics	1	0	0	0	1.00

Earnings & Valuation

This table compares Scinai Immunotherapeutics and Cardio Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.31 million	0.64	-$8.31 million	($95.34)	-0.01
Cardio Diagnostics	$10,000.00	553.52	-$6.50 million	($2.92)	-0.64

Cardio Diagnostics has lower revenue, but higher earnings than Scinai Immunotherapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Scinai Immunotherapeutics beats Cardio Diagnostics on 7 of the 11 factors compared between the two stocks.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.